UNSPSC 51182709: Metformin/sitagliptin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS502. This VA Drug Class (HS502) classifies this compound as belonging to the group ORAL HYPOGLYCEMIC AGENTS, ORAL.

UNSPSC 51182709 Metformin/sitagliptin is a Commodity code that nominally describes combination diabetes medications, but recent state and local solicitations under this code reflect a significant scope mismatch — the single posted opportunity targets naloxone and drug deactivation systems, which fall outside the pharmaceutical antidiabetic category. State and local procurement offices do not appear to be using this code for its intended pharmaceutical scope at present. The available record shows no issuing bodies soliciting metformin/sitagliptin products or related diabetes management medications through state and local procurement channels in the review window.

Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida and a response deadline of July 26, 2023. This naloxone and opioid-reversal procurement — while tagged to the metformin/sitagliptin code — represents emergency medicine and harm-reduction supply sourcing, not the antidiabetic pharmaceutical category the code nominally covers. The mismatch signals either a data-classification error in the state and local opportunity records or a coding practice divergence that does not reflect genuine buying activity under the metformin/sitagliptin commodity line. Firms pursuing pharmaceutical supply contracts to state and local health agencies should verify coding alignment before investing RFP response effort, as this code shows little relevant recent activity in its stated scope.